9,362
Participants
Start Date
March 9, 2017
Primary Completion Date
March 1, 2019
Study Completion Date
March 1, 2019
Medical tests
During Visit 1, subjects will go through medical tests including spirometry, bronchodilation test, pulse oximetry, cooximetry, and bioimpedance. Additional tests will be performed at up to 9 centers such as pulmonary diffusion test, 6 minute walk test, CT during the same visit.
Questionnaire
During Visit 1, subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Health Related Quality of Life (HRQoL) CAT questionnaire, HADS anxiety scale, YPAS physical activity questionnaire, ECSC respiratory symptoms questionnaire, occupational exposure related questionnaire, MMSE questionnaire, Fagerstrom test, Prochaska test.
GSK Investigational Site, Barcelona
GSK Investigational Site, Cáceres
GSK Investigational Site, Guadalajara
GSK Investigational Site, Huesca
GSK Investigational Site, Logroño
GSK Investigational Site, Madrid
GSK Investigational Site, Cartagena (Murcia)
GSK Investigational Site, Pamplona
GSK Investigational Site, Oviedo
GSK Investigational Site, Avilés/Asturias
GSK Investigational Site, Vigo-Pontevedra
GSK Investigational Site, Salamanca
GSK Investigational Site, La Laguna-Tenerife
GSK Investigational Site, Santander
GSK Investigational Site, Seville
GSK Investigational Site, Valencia
GSK Investigational Site, Zaragoza
GSK Investigational Site, Burgos
GSK Investigational Site, Pama de Mallorca
GSK Investigational Site, Vitoria-Gasteiz
Lead Sponsor
Collaborators (1)
IMS Health
OTHER
GlaxoSmithKline
INDUSTRY